Partner Headlines - POZN

  1. US Stock Futures Rise Ahead Of Earnings, Economic Data

    Benzinga
  2. POZEN Announces Receipt Of Three Patents From The United States ...

    Benzinga
  3. UPDATE: Ascendiant Capital Markets Upgrades Pozen Following Q2 ...

    Benzinga
  4. Markets Little Changed Ahead Of The Federal Reserve's Policy ...

    Benzinga
  5. Fed Says Districts Were Optimistic On Economic Outlook; Yahoo! ...

    Benzinga
  6. Yahoo Falls On Downbeat Results; Time Warner Shares Spike Higher

    Benzinga
  7. Morning Market Losers

    Benzinga
  8. Aura Of Light Shines On Pernix Shares Following Treximet Acquisition

    Benzinga
  9. POZEN Receives CRL From FDA

    Benzinga
  10. Morning Market Losers

    Benzinga
  11. Benzinga's Top #PreMarket Losers

    Benzinga
  12. Pozen Submits Final Study Report for PA8140/PA32540 Phase 1 Study ...

    Benzinga
  13. Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry ...

    Benzinga
  14. Will Horizon Pharma Spike Again On Quarterly Report?

    IBD
  15. Morning Market Losers

    Benzinga
  16. Benzinga's Top #PreMarket Losers

    Benzinga
  17. Benzinga's Top Downgrades

    Benzinga
  18. POZEN New PA8140/PA32540 PDUFA Date is April 25, 2014

    Benzinga
  19. POZEN Announces December 31, 2013 as Ex-Dividend Date for Previously ...

    Benzinga
  20. Benzinga's Top #PreMarket Gainers

    Benzinga
  21. POZEN Announces Special Cash Distribution of $1.75/Share

    Benzinga
  22. Horizon to Acquire US Rights for VIMOVO from Pozen

    Benzinga
  23. Benzinga's Top Pre-Market Gainers

    Benzinga
  24. Stocks To Watch For September 5, 2013

    Benzinga
  25. SANOFI

    IBD
  26. Sanofi, Pozen Announce Exclusive License Deal for Commercialization ...

    Benzinga
  27. Pozen Inc. Reports Operating Results (10-Q)

    GuruFocus
  28. UPDATE: Ascendiant Capital Markets Initiates POZEN at Buy; Future ...

    Benzinga
  29. POZEN Announces PA32540 Provides Superior Antiplatlet Effects ...

    Benzinga
  30. POZEN Provides Positive Update on Its PA Program and Results ...

    Benzinga
  31. POZEN Receives Patent on PA Products for Treatment of Cardiovascular ...

    Benzinga
  32. Celgene, Bed Bath & Beyond Among Stocks Gapping Down Thursday

    FoxBusiness
  33. Morning Market Losers

    Benzinga
  34. POZEN Says FDA Does Not Agree That BioEquivalence Was Demonstrated

    Benzinga
  35. POZEN Announces Licensing Deal with Desitin Arzneimittel GMBH ...

    Benzinga
Trading Center